Canine cancer drug fast-tracked for treating kids.

“New York-based biopharmaceutical company OS Therapies (OST) is focused on developing immunotherapies for osteosarcoma and other solid tumors. And it’s utilizing comparative oncology to achieve its goal. The company recently announced it had formed a subsidiary, OS Animal Health, to commercialize OST-HER2, its off-the-shelf canine osteosarcoma treatment, using clinical trial data to fast-track a treatment for kids with the same type of cancer.” ~ learn more